<DOC>
	<DOCNO>NCT00005829</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness gemcitabine treat patient recurrent chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Gemcitabine Treating Patients With Recurrent Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine rate duration complete partial remission patient recurrent B-cell chronic lymphocytic leukemia treat gemcitabine . II . Assess toxicity regimen patient . OUTLINE : Patients receive gemcitabine IV 30 minute day 1 8 . Treatment repeat every 4 week minimum 3 course . Patients achieve clinical complete remission , complete remission , nodular partial remission , partial remission follow 3 course therapy , receive 2 additional course therapy . Patients achieve complete remission improvement follow 2 additional course therapy , receive another 2 course therapy . Patients follow every 3 month disease progression relapse . Patients achieve complete remission follow every 6 month 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell chronic lymphocytic leukemia manifest follow : Minimum threshold peripheral lymphocyte count least 5,000/mm3 Small medium size peripheral blood lymphocyte great 55 % prolymphocytes Bone marrow aspirate biopsy contain least 30 % lymphoid cell Immunophenotypic biopsy evaluation peripheral blood lymphocyte demonstrate monoclonality B lymphocytes Bcell marker CD5 antigen ( e.g. , T1 , T101 ) absence pan Tcell marker ( e.g. , CD3 , CD2 ) Expression CD19 , CD20 , CD23 B cell surface marker Bcell expression kappa lambda light chain Active disease least one follow criterion : One disease relate symptom : At least 10 % weight loss within past 6 month Fever great 100.5 F least 2 week without evidence infection Night sweat without evidence infection Evidence progressive marrow failure manifest development worsen anemia ( hemoglobin le 11.0 g/dL ) and/or thrombocytopenia ( platelet count le 100,000/mm3 ) ( i.e. , stage III IV disease ) Autoimmune anemia and/or thrombocytopenia poorly responsive corticosteroid therapy Massive ( i.e. , great 6 cm leave costal margin ) progressive splenomegaly ( i.e. , great 50 % increase two month ) Massive ( i.e. , great 10 cm long diameter ) progressive lymphadenopathy ( i.e. , great 50 % increase two month ) Progressive lymphocytosis increase great 50 % 2 month period ( unrelated corticosteroid ) anticipate double time le 6 month No marked hypogammaglobulinemia development monoclonal protein absence criterion active disease Previously treat least fludarabine cladribine base regimen prior alkylating agent evidence recurrent progressive disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Platelet count least 75,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 1.5 time ULN ( unless due hemolysis chronic lymphocytic leukemia ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No New York Heart Association class III IV heart disease No myocardial infarction within past month Other : No uncontrolled infection HIV negative No active malignancy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy Endocrine therapy : See Disease Characteristics No concurrent corticosteroid Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 4 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
</DOC>